Journal list Promote Sponsor
verified SJR 1,82 · Q1 • database Scopus / SJR & Web of Science indexed
Critical Reviews in Oncology/Hematology
Ireland · Elsevier Ireland Ltd
workspace_premium Q1 — Hematology lock_open Open Access

Critical Reviews in Oncology/Hematology

Critical Reviews in Oncology/Hematology is a journal indexed in SJR in Hematology and Oncology with an H index of 153. It has an SJR impact factor of 1,82 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,82.

Critical Reviews in Oncology/Hematology focuses its scope in these topics and keywords: treatment, cancer, systematic, relapsed, review, radiotherapy, role, lesionsthe, options, promise, ...

ISSN: 1040-8428
Publisher: Elsevier Ireland Ltd
Category: Hematology
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
1,82 Q1
H-index 153
Acceptance rate pie_chart
22% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
NPD Open Access
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,82

H-index

153

Docs (year)

262

Docs 3y

648

Total refs

28575

Cites 3y

3804

Citable 3y

639

Cites/Doc 2y

5.97

Ref/Doc

109.06

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Phosphofructokinase: A mediator of glycolytic flux in cancer progression

View more

Why writing on ethics in oncology

View more

Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators

View more

The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer

View more

The role of cytokines in the normal and neoplastic pituitary

View more

The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas

View more

The human fibrinolytic system

View more

The treatment of undifferentiated neuroendocrine tumors

View more

Prostate cancer incidence and mortality trends among elderly and adult Europeans

View more

Promises and Challenges of Oncology and Hematology, Including Geriatric Oncology

View more

Prescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy?

View more

Pregnancy after breast cancer. The relationship of pregnancy to breast cancer development and progression

View more
SHOW MORE ARTICLES

Psychosocial issues

View more

Overcoming immunosuppression in bone metastases

View more

Originality, benefits and difficulties of clinical research performed by cooperative groups: the experience of an Italian Lung Cancer Study Group

View more

Originality, benefits and difficulties of clinical research performed by co-operative groups

View more

Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group

View more

Nerve sparing radical hysterectomy: latest developments and historical perspective

View more

Monoclonal antibodies and cancer

View more

Molecular markers predictive of response to chemotherapy in gastrointestinal tumors

View more

Microinvasive squamous cell cervical carcinoma

View more

Medical communications: techniques and strategies

View more

Mechanisms of the self/non-self-survey in the defense against cancer: Potential for chemoprevention?

View more

Management of patients with higher risk myelodysplastic syndromes

View more

FAQs